medigraphic.com

2021, Number 3

Next >>

Rev Hematol Mex 2021; 22 (3)

Seroprevalence of Trypanosoma cruzi in the eastern zone of Mexico City

Reboreda-Hernández ÓA, Ortiz-Butron R, Hernández-Peña S, Campos JL, Romero JC, Reyes-Maldonado E, González-Rodríguez N

Language: Spanish
References: 29
Page: 127-134
PDF size: 235.24 Kb.


ABSTRACT

Objective: To know the seroprevalence of Trypanosoma cruzi in the blood banks of the Western area of Mexico City.
Materials and Methods: A cross-sectional, descriptive study done from September 2017 to September 2018, in which the sera of individuals were analyzed using an ELISA commercial kit (with non-endemic strain antigens). These positive sera were studied with an ELISA homemade essay, and a Western Blot test (with endemic strain parasites). Moreover, the donators medical records were studied.
Results: There were obtained 512 sera from donators to the blood bank; 22% of those positive by commercial test were women. The mean age was 35 years; the age limits were 18 and 65 years. The different tests showed seroprevalence of 1.4%.
Conclusions: There is Chagas disease in a free vector area.


REFERENCES

  1. Zingales B. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Trop 2018; 184: 38-52. doi: 10.1016/j.actatropica.2017.09.017.

  2. Moure Z, Angheben A, Molina I, Gobbi F, Espasa M, Anselmi M, et al. Serodiscordance in chronic Chagas disease diagnosis: a real problem in non-endemic countries. Clin Microbiol Infect 2016; 22 (9): 788-92. doi: 10.1016/j. cmi.2016.06.001.

  3. Sanchez-Gonzalez G, Figueroa-Lara A, Elizondo-Cano M, Wilson L, Novelo-Garza B, Valiente-Banuet L, et al. Costeffectiveness of blood donation screening for Trypanosoma cruzi in Mexico. PLoS Negl Trop Dis 2016; 10 (3): e0004528. https://doi.org/10.1371/journal.pntd.0004528.

  4. Sanchez-Guillen MC, Barnabe C, Guegan JF, Tibayrenc M, Velasquez-Rojas M, Martinez-Munguia J, et al. High prevalence anti-Trypanosoma cruzi antibodies, among blood donors in the State of Puebla, a non-endemic area of Mexico. Mem Inst Oswaldo Cruz 2002; 97 (7): 947-52. https://doi.org/10.1590/S0074-02762002000700004.

  5. Navarro M, Monge-Maillo B, Flores-Chavez MD, Lopez- Velez R. Hunting hidden parasites: Trypanosoma cruzi. Lancet 2017; 390 (10096): 724-6. doi: 10.1016/S0140- 6736(17)31536-2.

  6. Moure Z. Serodiscordancia en el diagnóstico de la infección por Trypanosoma cruzi en área no endémica. Barcelona España: Universidad Autónoma de Barcelona; 2018.

  7. Reiche EM, Cavazzana M Jr., Okamura H, Tagata EC, Jankevicius SI, Jankevicius JV. Evaluation of the western blot in the confirmatory serologic diagnosis of Chagas’ disease. Am J Trop Med Hyg 1998; 59 (5): 750-6. doi: 10.4269/ ajtmh.1998.59.750.

  8. Coll-Cardenas R, Espinoza-Gomez F, Maldonado-Rodriguez A, Reyes-Lopez PA, Huerta-Viera M, Rojas-Larios F. Active transmission of human chagas disease in Colima Mexico. Mem Inst Oswaldo Cruz 2004; 99 (4): 363-8. https://doi. org/10.1590/S0074-02762004000400004.

  9. Alducin-Téllez ER-V, Medina-Yerbes I, Hernández O, López R, Peña-Hernández V, Monteón V. Prevalencia de serología positiva para Trypanosoma cruzi en pacientes con diagnóstico clínico de miocardiopatía dilatada en el Estado de Campeche, México. Arch Cardiol Mex 2011; 3: 204-7.

  10. Martinez-Tovar JG, Rebollar-Tellez EA, Fernandez Salas I. Seroprevalence of T. cruzi infection in blood donors and Chagas cardiomyopathy in patients from the coal mining region of Coahuila, Mexico. Rev Inst Med Trop Sao Paulo 2014; 56 (2): 169-74. doi: 10.1590/S0036- 46652014000200014.

  11. Padilla-Raygoza N, Gamboa-Leon R, Ramirez-Sierra MJ, Dumonteil E, Buekens P, Ruiz-Paloalto ML, et al. Negative studies are helpful to compute the specificity of diagnostic tests: measuring Trypanosoma cruzi seroprevalence in Guanajuato, Mexico. BMC Res Notes 2015; 8: 614. doi: 10.1186/s13104-015-1612-z.

  12. Molina-Garza ZJ, Bazaldua-Rodriguez AF, Quintanilla-Licea R, Galaviz-Silva L. Anti-Trypanosoma cruzi activity of 10 medicinal plants used in northeast Mexico. Acta Trop 2014; 136: 14-8. doi: 10.1016/j.actatropica.2014.04.006.

  13. Guzman-Gomez D, Lopez-Monteon A, de la Soledad Lagunes-Castro M, Alvarez-Martinez C, Hernandez-Lutzon MJ, Dumonteil E, et al. Highly discordant serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used for diagnostic. Parasit Vectors 2015; 8: 466. doi: 10.1186/s13071-015-1072-2.

  14. Hernandez-Romano P, Camara-Contreras M, Bravo-Sarmiento E, Lopez-Balderas N. Prevalence of Trypanosoma cruzi antibodies in blood donors from Veracruz State, Mexico. Transfusion 2015; 55 (3): 647-56. doi: 10.1111/ trf.12860.

  15. Monteon V, Solis-Oviedo R, Lopez R, Hernandez O, Tellez CA. Low seroprevalence of Trypanosoma cruzi infection and chronic chagasic cardiomyopathy in a region with abundance of triatomine vectors in Yucatan Peninsula of Mexico. Ann Parasitol 2015; 61 (4): 263-7. doi: 10.17420/ ap6104.17.

  16. Escamilla-Guerrero G, Martinez-Gordillo MN, Riveron- Negrete L, Aguilar-Escobar DV, Bravo-Lindoro A, Cob-Sosa C, et al. Trypanosoma cruzi: seroprevalence detected in the blood bank of the Instituto Nacional de Pediatria, Mexico City, in the period 2004 through 2009. Transfusion 2012; 52 (3): 595-600. doi: 10.1111/j.1537-2995.2011.03322.x.

  17. Secretaría de Salud Gobierno de Mexico Manual de Procedimientos para la Enfermedad de Chagas en México, 2019.

  18. CENSIDA. CENSIDA 2019 [cited 2019 15-08-19]. Available from: https://www.gob.mx/censida.

  19. OMS. Enfermedad de Chagas 2019 [updated 01-08-2019. Available from: https://www.who.int/topics/chagas_disease/ es/.

  20. Eguez KE, Alonso-Padilla J, Teran C, Chipana Z, Garcia W, Torrico F, et al. Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. PLoS Negl Trop Dis 2017; 11 (4): e0005501. doi: 10.1371/journal.pntd.0005501.

  21. Ramos-Ligonio A, Ramírez-Sánchez ME, González-Hernández JC, Rosales-Encina JL, López-Monteón A. Prevalence of antibodies against Trypanosoma cruzi in blood bank donors from the IMSS General Hospital in Orizaba, Veracruz, México. Salud Publica Mex 2006; 48 (1): 13-21.

  22. NORMA Oficial Mexicana NOM-253-SSA1-2012, (2016).

  23. Guzman-Gomez D, Lopez-Monteon A, de la Soledad Lagunes-Castro M, Alvarez-Martinez C, Hernandez-Lutzon MJ, Dumonteil E, et al. Highly discordant serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used for diagnostic. Parasit Vectors 2015; 8: 466. doi: 10.1186/s13071-015-1072-2.

  24. Secretaría de Salud Gobierno de México Centro Nacional de Transfusión Sanguínea. Informes mensuales de ingresos y egresos de sangre y sus componentes y enfermedades transmisibles por transfusión, 2012.

  25. Galvao LM, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade AL. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol. 2003; 41 (11): 5066-70. https://doi. org/10.1128/JCM.41.11.5066-5070.2003.

  26. Velasco-Castrejon O, Valdespino JL, Tapia-Conyer R, Salvatierra B, Guzman-Bracho C, Magos C, et al. [Seroepidemiology of Chagas disease in Mexico]. Salud Publica Mex 1992; 34 (2): 186-96.

  27. PAHO. Enfermedad de Chagas 2019 [updated 15-08- 19. Available from: https://www.paho.org/hq/index. php?option=com_content&view=article&id=5856:2011- informacion-general-enfermedad-chagas&Itemid=4037 0&lang=es.

  28. CNTS. Donacion Altruista 2015 [updated 2015. Available from: https://www.gob.mx/cms/uploads/attachment/ file/47749/Donaci_n_de_sangre.pdf.

  29. CNTS. Centro Nacional de la Transfusion Sanguinea 2019 [Available from: https://www.gob.mx/cnts.




2020     |     www.medigraphic.com